Quiz
Second-Line Therapy in Chronic Graft-Versus-Host Disease (cGVHD)
News
09/17/2026
Emily Estrada
Results from a phase 3 trial demonstrated that replacing mycophenolate mofetil with low-dose ruxolitinib significantly reduced acute graft-versus-host disease following haploidentical hematopoietic stem-cell transplantation, supporting...
Results from a phase 3 trial demonstrated that replacing mycophenolate mofetil with low-dose ruxolitinib significantly reduced acute graft-versus-host disease following haploidentical hematopoietic stem-cell transplantation, supporting...
Results from a phase 3 trial...
09/17/2026
Oncology
News
06/16/2026
Emily Estrada
Results from a phase 3 trial demonstrated that post-transplant cyclophosphamide did not achieve noninferiority to anti–T-lymphocyte globulin for overall survival following unrelated donor alloHCT in patients with high-risk myeloid...
Results from a phase 3 trial demonstrated that post-transplant cyclophosphamide did not achieve noninferiority to anti–T-lymphocyte globulin for overall survival following unrelated donor alloHCT in patients with high-risk myeloid...
Results from a phase 3 trial...
06/16/2026
Oncology
FDA Approval
05/07/2026
Stephanie Holland
Based on pharmacokinetic bioequivalence data, the FDA has approved extended-release ruxolitinib for patients with myelofibrosis, polycythemia vera, and graft-versus-host disease.
Based on pharmacokinetic bioequivalence data, the FDA has approved extended-release ruxolitinib for patients with myelofibrosis, polycythemia vera, and graft-versus-host disease.
Based on pharmacokinetic...
05/07/2026
Oncology
Infographic
09/16/2025
This easy-to-view infographic showcases adverse event management considerations to help better support patients being treated with axatilimab.
This easy-to-view infographic showcases adverse event management considerations to help better support patients being treated with axatilimab.
This easy-to-view infographic...
09/16/2025
Oncology
Specialties
